Key result
Pharmacogenetic-guided warfarin loading achieves therapeutic INR ~1.5 days faster than maintenance dosing in postpartum PE.
Why the study?
Warfarin is typically used in a fixed loading dose regimen that may increase bleeding risk or prolong time to reach standard dose.
Does a pharmacogenetic-guided loading dose of warfarin reduce the time to reach therapeutic INR in postpartum women with pulmonary embolism compared to a maintenance dose?
RCT (n=64)
Double-blind
1:1
No
Does a pharmacogenetic-guided loading dose of warfarin reduce the time to reach therapeutic INR in postpartum women with pulmonary embolism compared to a maintenance dose?
A pharmacogenetic-guided loading dose of warfarin significantly reduced the time to reach therapeutic INR compared to a maintenance dose in postpartum women with pulmonary embolism, without increasing bleeding risks.
Answers are grounded in this paper and cite their sources.
Pharmacogenetic-guided warfarin loading shortens time to therapeutic INR in postpartum PE without excess bleeding; extends IWPC model validation to this population.
Purpose: Warfarin is usually used in a fixed loading dose regimen, which may increase the risk of bleeding or prolong the time to reach standard dose. The aim of the study is to compare the efficacy and safety of loading dose versus maintenance dose of warfarin therapy in postpartum women with pulmonary embolism (PE) under the guidance of clinical pharmacogenetic information. Patients and Methods: A total of 64 postpartum women with PE were recruited from September 2022 to August 2023. Participants were randomly divided 1:1 into two groups using a random-number table patients in the experimental group received a regimen combining the initial 1 to 3 days loading dose with the International Warfarin Pharmacogenetics Consortium (IWPC) model. Patients in the control group only received a regimen guided by the IWPC model for the initial 1 to 3 days. Starting from day 4, the warfarin dose was adjusted according to the international normalized ratio (INR). The primary outcome was first time to therapeutic INR (2.0-3.0). Results: The study found that the median time to first reach the therapeutic INR was 5.5 days in the experimental group compared to 7 days in the control group (p=0.002). The median time within therapeutic range (TTR) was 97.24% in the experimental group compared to 95.50% in the control group (p=0.001). The difference in adverse events showed no statistical significance between the two groups (P > 0.05). Conclusion: The study could provide ideas for the precise treatment of warfarin in postpartum women with PE. The integration of warfarin loading doses guided by pharmacogenetics into clinical practice can enhance decision-making, optimize patient outcomes, and reduce adverse events.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) conducted an RCT in Pulmonary embolism in postpartum women (n=64). Warfarin (pharmacogenetic-guided loading dose) vs. Warfarin (pharmacogenetic-guided maintenance dose) was evaluated on Time to first reach therapeutic INR (2.0-3.0) in days (p=0.002). A pharmacogenetic-guided loading dose of warfarin reduced the median time to first reach therapeutic INR to 5.5 days compared to 7 days with a maintenance dose in postpartum women with PE.
Synapse has enriched 10 related papers. Consider them for comparative context: